MRPL27: A Potential Drug Target and Biomarker (G51264)

Target Name: MRPL27

NCBI ID: G51264

MRPL27

MRPL27: A Potential Drug Target and Biomarker

MRP (MutL-RISC Pathway) is a protein that plays a crucial role in the regulation of DNA double-strand break repair in eukaryotic cells. Mutations in the MRP gene have been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders . One of the most promising lead compounds identified in the search for MRP inhibitors is MRPL27, a potential drug target and biomarker.

The MutL-RISC Pathway

The MutL-RISC (Mutations Recognizable by linker- eluted restriction-site) pathway is a non-coding RNA-protein interaction network that plays a central role in the regulation of DNA double-strand break repair in eukaryotic cells. It consists of several proteins , including MRP (MutL-RISC Regulatory Protein), MSK (MutL-RISC Structural Protein), and MSP (MutL-RISC Server).

MRP, a 27-kDa protein, is the most well-studied protein of the MutL-RISC pathway. It is involved in the recognition of DNA double-strand breaks and in the repair of these breaks. MRP has three structural domains: a N -terminal domain that contains a leucine-rich repeat (LRR), a central domain that contains a domain with homology to the switch I protein, and a C-terminal domain that contains a domain with homology to the switch II protein.

LRR is a common structural motif that is found in various proteins, including DNA-binding proteins, RNA-binding proteins, and protein-ligating proteins. LRRs often have a positively charged side and a negatively charged side, which can interact with other proteins. The N-terminal domain of MRP contains a specific LRR that is involved in the interaction with MSK, the protein that it binds to in the central domain.

The Central Domain

The central domain of MRP contains a protein-ligating domain (PDD) and a nucleotide-binding domain (NBD). The PDD is a structural domain that contains a nucleotide-binding loop and a conserved water-binding site. The NBD is a structural domain domain that contains a nucleotide-binding loop and a conserved acid-binding site.

The PDD and NBD in the central domain of MRP interact with each other to form a complex that is involved in the recognition of DNA double-strand breaks. The PDD binds to the nucleotide-binding loop of the NBD, while the NBD binds to the PDD. This interaction between the PDD and NBD is critical for the function of MRP.

The C-Terminal Domain

The C-terminal domain of MRP contains a protein-ligating domain (CLD) and a conserved nucleotide-binding loop (NBL). The CLD is a structural domain that contains a nucleotide-binding loop and a conserved water-binding site. The NBL is a structural domain that contains a nucleotide-binding loop and a conserved acid-binding site.

The CLD and NBL in the C-terminal domain of MRP interact with each other to form a complex that is involved in the recognition of DNA double-strand breaks. The CLD binds to the nucleotide-binding loop of the NBL, while the NBL binds to the CLD. This interaction between the CLD and NBL is critical for the function of MRP.

MRPL27: A Potential Drug Target

The potential drug target for MRPL27 is its interaction with MSK, the protein that it binds to in the central domain. MSK is a 21-kDa protein that is also involved in the regulation of DNA double-strand break repair in eukaryotic cells. It has a nucleotide-binding domain (NBD) and a protein-ligating domain (PLD

Protein Name: Mitochondrial Ribosomal Protein L27

The "MRPL27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets